Independent Director · Bicara Therapeutics Inc. (BCAX)

Kiran Mazumdar-Shaw — Bicara Therapeutics Director Compensation (2025)

Fiscal year 2025 director compensation for Kiran Mazumdar-Shaw at Bicara Therapeutics Inc.. Every figure below is printed as the company filed it and cited to the filing it came from.

Director compensation as of the proxy filed April 27, 2026 (DEF 14A). Open the filing on EDGAR.

What they were paid

Bicara Therapeutics Director Compensation Table · the one fiscal year held
In US dollars, as Bicara Therapeutics reports it. Most recent year first. Totals are the company’s disclosed totals.
Fiscal yearCash feesStock awardsOption awardsOtherTotal
FY2025$44,000—$208,634—$252,634

Each year as stated in that year's proxy. A dash means the company reported no figure in that column. Source: Bicara Therapeutics Inc. DEF 14A filed April 27, 2026, accession 0001628280-26-027320, and prior-year filings. Open the filing on EDGAR.

How this board is paid

company policy · FY2025

Bicara Therapeutics pays directors a $40,000 cash retainer and $47,492 in Options.

The rest of the Bicara Therapeutics board

FY2025 · as the company reported each
DirectorRoleFY2025 total
Carolyn NgIndependent Director$0
Christopher BowdenIndependent Director$253,634
Jake SimsonIndependent Director$252,634
Kate HavilandIndependent Director$253,634
Michael PowellIndependent Director$296,134
Nils LonbergIndependent Director$256,634
Scott RobertsonIndependent Director$263,634

The full Bicara Therapeutics compensation record

free company brief

This page is one director within Bicara Therapeutics's record. The company brief lists every named executive and director, each linking to their own page.

Velarion Pro: every company page, peer tools and exports, one seat

One email to you when Pro opens, and nothing else. Privacy